Medical News Updates

About Medical News Updates

Welcome to "Medical News Updates," the go-to channel for anyone eager to understand complex medical news in a straightforward, simplified manner. Our mission is to break down the latest health studies and medical news into easy-to-digest information that makes sense to everyone, especially those without a medical background. What We Offer: Weekly Medical News: Stay updated with the latest happenings in the medical world, explained in plain language. Exploring Health Studies: We translate complex data from new health studies into clear, understandable summaries. Why Subscribe? Understand Your Health Better: We believe that knowledge is power, and understanding the medical news that affects you and your family should be straightforward, not confusing. Trustworthy Information: Experts in medical communication have interpreted and sourced all of our content from reliable medical journals. Community of Like-Minded Individuals: Join a community where curiosity is encouraged, and learning about health is fun and engaging.

Publisher

FWA

Category

education

Language

en

Explicit

No

First episode

13 Apr 2024

Latest episode

16 Sept 2026

Latest episodes

30 episodes in the feed.

1. 

   16 Sept 2026

   Stopping a GLP-1, a Blood Test Worth a Second Look, and What Is in Your Glass

   This week: how quickly weight returns after stopping semaglutide or tirzepatide, why a borderline normal haemoglobin may deserve a closer look, twelve month results for automated insulin delivery in type 1 diabetes, why the testosterone dose matters for heart rhythm, and what two million people can and cannot tell us about drinks and mood. In this episode. Weight regain after stopping a GLP-1, from a pooled analysis of six randomised trials in Endocrinology, Diabetes and Metabolism. Borderline low haemoglobin and mortality, from half a million adults in the UK Biobank, published in Annals of Internal Medicine. Automated insulin delivery at twelve months in adults with type 1 diabetes. Testosterone and atrial fibrillation, and why the target level matters, from the Journal of the Endocrine Society. Drinks, depression and anxiety, from fifty-nine studies covering more than two million people. Every story carries its caveat in the episode. Correlation is not causation, and preliminary findings are flagged as preliminary. This is general education, not personal medical advice. Please talk to your own clinician about your care.

2. 

   6 Sept 2026

   Statins After Seventy, and a Sick Day Rule Worth Writing Down

   This week: a large trial finds statins cut heart attacks and strokes in healthy over seventies but do not prevent dementia or disability, a Scandinavian study of more than 280,000 people pins down who is most at risk of ketoacidosis on flozin medicines, semaglutide and tirzepatide enter the European heart failure guidelines, immune cells appear to remember obesity for years, and four medical bodies issue joint autumn vaccine advice. statins, atorvastatin, STAREE trial, primary prevention, healthy ageing, SGLT2 inhibitors, flozins, diabetic ketoacidosis, sick day rules, type 2 diabetes, heart failure, ESC guidelines, semaglutide, tirzepatide, GLP-1, obesity, weight loss, immune system, flu vaccine, COVID vaccine, RSV

3. 

   1 Sept 2026

   A Sensor That Sees DKA Coming, Statins After 70, and a First for Pancreatic Cancer

   This week in plain English: the first wearable that tracks glucose and ketones together, the STAREE trial on statins for healthy over 70s, why missed blood pressure pills erase their benefit, the first RAS targeted drug for pancreatic cancer, and new guidelines on cardiac rehab. Source: FDA press release, 25 Aug 2026, Libre Duo 10 Day authorization: https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar (https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar) Healio, first continuous ketone and glucose device authorized: https://www.healio.com/news/endocrinology/20260826/first-device-to-continuously-monitor-ketone-and-glucose-levels-receives-fda-authorization (https://www.healio.com/news/endocrinology/20260826/first-device-to-continuously-monitor-ketone-and-glucose-levels-receives-fda-authorization) UPI coverage of the Libre Duo authorization: https://www.upi.com/Top_News/US/2026/08/25/fda-oks-blood-sugar-ketone-monitor/5521787688375/ (https://www.upi.com/Top_News/US/2026/08/25/fda-oks-blood-sugar-ketone-monitor/5521787688375/) Medscape, STAREE results at ESC 2026: https://www.medscape.com/viewarticle/staree-trial-atorvastatin-cuts-major-cv-events-30-older-2026a1000ukk (https://www.medscape.com/viewarticle/staree-trial-atorvastatin-cuts-major-cv-events-30-older-2026a1000ukk) TCTMD, STAREE, statins cut MACE risk 30 percent in older adults: https://www.tctmd.com/news/staree-statins-cut-mace-risk-30-older-adults-no-cvd-history (https://www.tctmd.com/news/staree-statins-cut-mace-risk-30-older-adults-no-cvd-history) Healio, statins after age 70: https://www.healio.com/news/cardiology/20260829/statins-cut-risk-for-first-heart-attack-stroke-by-30-after-age-70 (https://www.healio.com/news/cardiology/20260829/statins-cut-risk-for-first-heart-attack-stroke-by-30-after-age-70) ESC press release, blood pressure medication adherence analysis (BPLTTC): https://www.escardio.org/news/press/press-releases/patients-are-missing-out-on-the-cardiovascular-benefits-of-blood-pressure-lowering-medicines/ (https://www.escardio.org/news/press/press-releases/patients-are-missing-out-on-the-cardiovascular-benefits-of-blood-pressure-lowering-medicines/) HCPLive, low adherence cuts cardiovascular benefit of blood pressure therapy: https://www.hcplive.com/view/low-adherence-cuts-cardiovascular-benefit-of-blood-pressure-therapy (https://www.hcplive.com/view/low-adherence-cuts-cardiovascular-benefit-of-blood-pressure-therapy) FDA press release, 26 Aug 2026, Rasonque (daraxonrasib) approval: https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer (https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer) AJMC, daraxonrasib clears FDA as first RAS targeted pancreatic cancer drug: https://www.ajmc.com/view/daraxonrasib-clears-fda-as-first-ras-targeted-pancreatic-cancer-drug (https://www.ajmc.com/view/daraxonrasib-clears-fda-as-first-ras-targeted-pancreatic-cancer-drug) News Medical, new international guidelines on cardiac rehabilitation: https://www.news-medical.net/news/20260828/New-international-guidelines-highlight-the-extensive-benefits-of-cardiac-rehabilitation.aspx (https://www.news-medical.net/news/20260828/New-international-guidelines-highlight-the-extensive-benefits-of-cardiac-rehabilitation.aspx) Mirage News, first ESC cardiac rehab guidelines: https://www.miragenews.com/first-esc-cardiac-rehab-guidelines-highlight-1734933/ (https://www.miragenews.com/first-esc-cardiac-rehab-guidelines-highlight-1734933/)

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

YouTube views

205,198

Score snapshot 15 Sept 2025

Podcast Authority Score: 32 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

27

Social presence

0

YouTube

93

Engagement

0

Contact Medical News Updates

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.